BIOADAPTIVES, INC.
BIOADAPTIVES, INC. (BDPT): 30 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.1 months
D/E -1.06 · 0% dilution
Lead: Approved
30 candidates
N/A
N/A
A transparent, data-derived signal for BIOADAPTIVES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$44K
Cash
$74K
Quarterly Burn
$85K
Runway
3.1 mo
Revenue
$6K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (30 candidates)
Showing 10 of 30 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in BIOADAPTIVES, INC.'s pipeline?
BIOADAPTIVES, INC. (BDPT) has 30 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOADAPTIVES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOADAPTIVES, INC. has approximately 3.1 months of cash runway.
What is BIOADAPTIVES, INC.'s market capitalization?
BIOADAPTIVES, INC.'s market capitalization is approximately $44K.
Who is the CEO of BIOADAPTIVES, INC.?
Mr. James E. Keener is the chief executive officer of BIOADAPTIVES, INC. (BDPT).
Get the full picture on BIOADAPTIVES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.